Day: August 13, 2021

TORONTO, Aug. 13, 2021 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan”) (TSX: REI.UN) today announced a distribution of 8 cents per unit for the month of August. The distribution will be payable on September 8, 2021 to unitholders of record as at August 31, 2021. About RioCan RioCan is one of Canada’s largest real estate investment trusts. RioCan owns, manages and develops retail-focused, increasingly mixed-use properties located in prime, high-density transit-oriented areas where Canadians want to shop, live and work. As at June 30, 2021, our portfolio is comprised of 214 properties with an aggregate net leasable area of approximately 37.2 million square feet (at RioCan’s interest) including office, residential rental and 15 development properties. To learn more about us, please visit www.riocan.com. Information...

MÜV Tampa—West Kennedy is Verano’s 36th Florida dispensary, and the Company’s 84th overall. Later this month, Verano plans to open MÜV Orange City, its 37th Florida storefront. MÜV Tampa—West Kennedy sits on Kennedy Boulevard, a major east-west corridor in downtown Tampa and is centrally located between high-traffic destinations such as Raymond James Stadium, the Tampa Riverwalk, Sparkman Wharf, and Westshore Plaza Shopping and Dining. Tampa is Florida’s third largest metro area with a population of over 3.1 million residents and sees approximately 23 million visitors annually. West Kennedy Boulevard has an average daily traffic count of over 33,000 cars, according to the Florida Department of Transportation.CHICAGO, Aug. 13, 2021 (GLOBE NEWSWIRE) — Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”),...

–-Type A meeting with FDA expected late Q3 to define pathway to potential approval for Oral Sulopenem following July’s Complete Response Letter– –Cash Runway into Second Half of 2023–  –Company to host conference call today at 8:30am ET– DUBLIN, Ireland and CHICAGO, Aug. 13, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2021. “Despite our disappointment with the FDA’s Complete Response Letter (“CRL”), we’ve begun preparations for the Type A meeting with the FDA expected later this quarter and we hope to receive...

$48.2 million in cash and short-term investments, pre-development activities commenced VANCOUVER, British Columbia, Aug. 13, 2021 (GLOBE NEWSWIRE) — Sabina Gold & Silver Corp. (“Sabina”) or (the “Company”) (SBB – TSX/ SGSVF – OTCQX) reports the interim financial results for the six months ended June 30, 2021. “Sabina had a safe and productive second quarter with strong advancement of Goose site activities and other corporate initiatives,” said Bruce McLeod, President & CEO. “Planned exploration drilling for 2021 has wrapped up successfully and pre-development activities continue with advancement of the Umwelt underground exploration ramp and other site works including road construction and plant and camp laydown preparation. During the quarter, logistics and readiness planning was initiated at the Port facility...

— Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021 — Management hosting conference call and webcast today at 8:30 AM ET TORONTO and HOUSTON, Aug. 13, 2021 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended June 30, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted. “We are off to a strong start in fiscal 2022 and well positioned for continued success with a steady frequency of value creating milestones expected over the coming year,” said Fahar Merchant, PhD, President and CEO of Medicenna. “We are on track to initiate...

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported second quarter financial results for the period ending June 30, 2021. “Our clinical and manufacturing momentum is a testament to our confidence in efruxifermin (EFX), which has the potential to be among the first investigational NASH therapies approved for treatment of both pre-cirrhotic (F2/F3) and cirrhotic (F4) NASH,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “We are excited to initiate our second Phase 2b clinical trial in patients with late-stage cirrhotic NASH (F4), who are at increased risk of liver failure and thus have the highest unmet medical need.” Second...

FORT MILL, S.C., Aug. 13, 2021 (GLOBE NEWSWIRE) — Diversey Holdings, Ltd. (“Diversey”) (NASDAQ: DSEY) announced Q2 results with continued strength in Food & Beverage and better than expected recovery in base Institutional business in countries where reopenings have begun. SECOND QUARTER HIGHLIGHTSReported Q2 net sales grew 3.9% vs 2020 with continued strength in Food & Beverage, encouraging base Institutional recovery in the countries where re-openings are more advanced and favorable foreign currency translation, offset by some infection prevention revenue normalization versus very strong gains last year. Reported Q2 net sales declined 4.4% vs pre-COVID 2019 baseline as global lockdowns continued to impact many sectors, including education, office buildings, hospitality and food service. Net loss of $1.3...

First quarter revenue up 23% over prior yearStrong cash balance of $770 millionContinuing to advance therapeutics portfolio to drive future revenue growth SUNNYVALE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today reported its financial results for the first quarter of its fiscal year 2022 (Q1 FY2022), which ended June 30, 2021. “We are excited to announce our first quarterly earnings results and engage as a publicly traded company. I’m grateful to our customers, investors and employees who power our mission to help people access, understand and benefit from the human genome,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “We believe that genetic information is the future of personalized medicine. Our unique research platform enables...

Longeveron to hold conference call today at 8:00 AM EDT MIAMI, Aug. 13, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the quarter ended June 30, 2021. “We continue to make excellent progress advancing our Lomecel-B clinical research programs forward,” said Geoff Green, CEO of Longeveron. “Today we announced encouraging top-line results from our Phase 2b Aging Frailty trial evaluating the safety and efficacy of four different doses of Lomecel-B compared to placebo in Aging Frailty subjects. And, we anticipate announcing top-line results from our other Phase 1/2 Aging Frailty...

CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three and six months ended June 30, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated. “The second quarter 2021 was an important period for Trillium, during which time we communicated our go-forward strategy and began executing against it,” said Jan Skvarka, Trillium’s President and CEO. “We announced seven priority indications and nine patient settings, with six studies expected to initiate in 2021. As of today, we have already initiated four studies, including in multiple myeloma, acute myeloid leukemia (p53 mutated and wild...